

# Scales

## FY20 Result — Growing Pains

GUY HOOPER

guy.hooper@forsythbarr.co.nz  
+64 4 495 5255

NEUTRAL 

Scales (SCL) reported a soft FY20 result, as Horticulture weakness offset a surging Food Ingredients business. Pet food strength was a highlight in FY20, however, the key takeaway was the dampened outlook commentary and a downgrade to FY21 earnings guidance, cut -10% at the mid-point from its previous range. Weighing on earnings expectations are lower fruit production and Horticulture margin pressure. We lower our earnings forecasts and cut our target price -30cps to NZ\$5.00. While SCL offers attractive medium-term earnings growth, it faces elevated near-term earnings risk (labour shortages) and a more opaque market outlook. We view risk reward as broadly fair. Reiterate our NEUTRAL rating.

NZX Code	SCL	Financials: Dec/	20A	21E	22E	23E	Valuation (x)	20A	21E	22E	23E
Share price	NZ\$4.60	NPAT* (NZ\$m)	26.6	29.5	35.0	39.5	PE	24.4	22.0	18.5	16.4
Target price	NZ\$5.00	EPS* (NZc)	18.9	20.9	24.9	28.0	EV/EBIT	15.9	14.6	12.9	11.5
Risk rating	Medium	EPS growth* (%)	-45.4	10.9	18.8	12.8	EV/EBITDA	10.5	10.3	9.4	8.6
Issued shares	140.9m	DPS (NZc)	19.0	19.0	21.0	22.0	Price / NTA	2.0	1.9	1.9	1.8
Market cap	NZ\$648m	Imputation (%)	100	100	100	100	Cash div yld (%)	4.1	4.1	4.6	4.8
Avg daily turnover	116.7k (NZ\$554k)	*Based on normalised profits					Gross div yld (%)	5.7	5.7	6.3	6.6

### What's changed?

- **Earnings:** We cut our FY21E NPAT forecast -13% to NZ\$29.5m. We also lower FY22 and FY23 NPAT forecasts -6% and -3% respectively, reflecting margin pressure through the Horticulture business.
- **Target price:** Our target price falls -30cps (-6%) to NZ\$5.00 as a result of earnings changes and higher cost of capital assumptions.

### Key take outs from SCL's FY20 result

- **Soft Horticulture with suppressed margin outlook** — SCL's soft Horticulture earnings were well signalled. Asian market price weakness weighed on revenue, while ongoing wage inflation impacted margin. Although the selling environment appears to have improved, we expect to see earnings weakness given 1) a lower expected crop, and 2) harvest risk and cost inflation due to low seasonal labour availability.
- **Food Ingredients growth the stand out but margin sustainability a question** — FY20 Food Ingredients EBITDA increased +71% on the prior year period to NZ\$23m, supported by a structural demand tailwind for pet food and underpinned by margin expansion. EBITDA dollar/kg increased +64% on the prior year to NZ\$0.20/kg (FY19 NZ\$0.12/kg). We suspect margin growth was driven by supply demand dynamics, with meat works impacted by COVID-19 restrictions. However, margin reversion in FY21 is likely, and therefore we forecast a slight decline in Food Ingredients earnings.
- **NZ\$98m cash balance for acquisitions** — Travel restrictions have weighed on SCL's ability to pursue bolt-on US pet food acquisitions, although expect pet food will be an area of incremental investment, with additional protein lines an opportunity to broaden its portfolio. SCL continues to pursue possible transformational acquisitions, with c. NZ\$250m capacity on its balance sheet.

### Guidance lowered with near-term headwinds signalled

SCL lowered its NPAT guidance range -10% at the mid-point to NZ\$27.5m–NZ\$32.5m (previously NZ\$30m–NZ\$36m). Although we expect earnings across the group to decline, the softer outlook is again primarily driven by the Horticulture business which is facing a number of headwinds in FY21 including: 1) lower third-party export volumes as a result of an adverse weather event in Tasman, 2) lowered own grown harvest expectations, 3) shipping congestion, and 4) labour shortage challenges.

## Scales Corporation (SCL)

Priced as at 26 Feb 2021 (NZ\$) **4.60**

<b>12-month target price (NZ\$)*</b>	<b>5.00</b>
Expected share price return	8.7%
Net dividend yield	4.2%
Estimated 12-month return	12.9%

<b>Key WACC assumptions</b>	
Risk free rate	2.30%
Equity beta	0.99
WACC	6.9%
Terminal growth	1.5%

<b>Spot valuations (NZ\$)</b>	
1. DCF	5.12
2. Comparative multiples	4.80
3. n/a	n/a

<b>DCF valuation summary (NZ\$m)</b>	
Total firm value	796
(Net debt)/cash	98
Less: Capitalised operating leases	(160)
Value of equity	734

<b>Profit and Loss Account (NZ\$m)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>	<b>Valuation Ratios</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>
Sales revenue	484.6	470.7	475.9	526.6	557.1	EV/EBITDA (x)	8.6	9.3	9.0	8.1	7.4
<b>Normalised EBITDA</b>	<b>72.0</b>	<b>56.7</b>	<b>59.2</b>	<b>65.8</b>	<b>72.0</b>	EV/EBIT (x)	10.0	14.0	12.8	11.2	9.9
Depreciation and amortisation	(18.1)	(19.2)	(17.8)	(17.9)	(18.1)	PE (x)	13.3	24.4	22.0	18.5	16.4
<b>Normalised EBIT</b>	<b>61.8</b>	<b>37.6</b>	<b>41.5</b>	<b>47.9</b>	<b>53.8</b>	Price/NTA (x)	2.1	2.0	1.9	1.9	1.8
Net interest	(3.8)	(2.3)	(1.6)	(1.2)	(1.1)	Free cash flow yield (%)	6.2	4.4	5.1	6.6	7.6
Associate income	0	0	0	0	0	Net dividend yield (%)	4.1	4.1	4.1	4.6	4.8
Tax	9.4	8.7	10.4	11.7	13.2	Gross dividend yield (%)	5.7	5.7	5.7	6.3	6.6
Minority interests	3.6	5.6	3.6	4.0	4.2						
<b>Normalised NPAT</b>	<b>48.6</b>	<b>26.6</b>	<b>29.5</b>	<b>35.0</b>	<b>39.5</b>	<b>Capital Structure</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>
Abnormals/other	0	0	0	0	0	Interest cover EBIT (x)	16.3	16.2	25.6	39.4	47.3
<b>Reported NPAT</b>	<b>121.6</b>	<b>26.6</b>	<b>29.5</b>	<b>35.0</b>	<b>39.5</b>	Interest cover EBITDA (x)	19.0	24.5	36.6	54.2	63.2
Normalised EPS (cps)	34.6	18.9	20.9	24.9	28.0	Net debt/ND+E (%)	-41.9	-35.8	-32.3	-33.4	-35.2
DPS (cps)	19.0	19.0	19.0	21.0	22.0	Net debt/EBITDA (x)	n/a	n/a	n/a	n/a	n/a
<b>Growth Rates</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>Key Ratios</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>
Revenue (%)	20.4	-2.9	1.1	10.6	5.8	Return on assets (%)	11.1	6.4	7.0	7.9	8.6
EBITDA (%)	39.2	-21.2	4.4	11.1	9.3	Return on equity (%)	13.7	7.1	7.8	8.9	9.7
EBIT (%)	45.4	-39.2	10.4	15.5	12.4	Return on funds employed (%)	12.2	7.1	7.6	8.5	9.3
Normalised NPAT (%)	69.8	-45.3	10.9	18.8	12.8	EBITDA margin (%)	14.9	12.1	12.4	12.5	12.9
Normalised EPS (%)	69.5	-45.4	10.9	18.8	12.8	EBIT margin (%)	12.7	8.0	8.7	9.1	9.7
Ordinary DPS (%)	0.0	0.0	0.0	10.5	4.8	Capex to sales (%)	3.2	5.2	2.5	2.2	2.0
						Capex to depreciation (%)	87	128	68	65	62
						Imputation (%)	100	100	100	100	100
						Pay-out ratio (%)	55	101	91	84	78
<b>Cash Flow (NZ\$m)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>	<b>Operating Performance</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>
<b>EBITDA</b>	<b>72.0</b>	<b>56.7</b>	<b>59.2</b>	<b>65.8</b>	<b>72.0</b>	<b>Revenue split (division)</b>					
Working capital change	13.9	4.1	(6.6)	(2.8)	(1.7)	Horticulture	264.8	246.0	233.3	260.0	273.8
Interest & tax paid	(13.2)	(11.0)	(15.0)	(16.0)	(17.5)	Logistics	64.1	49.8	51.3	54.7	57.5
Other	(16.6)	3.4	7.6	7.7	7.9	Food Ingredients	155.1	173.7	191.4	211.9	225.8
<b>Operating cash flow</b>	<b>56.1</b>	<b>53.2</b>	<b>45.2</b>	<b>54.7</b>	<b>60.6</b>	<b>Total</b>	<b>484.6</b>	<b>470.7</b>	<b>475.9</b>	<b>526.6</b>	<b>557.1</b>
Capital expenditure	(15.7)	(24.5)	(12.1)	(11.7)	(11.2)						
(Acquisitions)/divestments	162.9	0.2	0	0	0	<b>EBITDA split (division)</b>					
Other	0	0	(6.5)	(6.6)	(6.8)	Horticulture	47.9	35.8	39.7	46.8	52.0
<b>Funding available/(required)</b>	<b>203.3</b>	<b>28.9</b>	<b>26.6</b>	<b>36.4</b>	<b>42.7</b>	Logistics	4.9	4.2	3.3	3.8	4.0
Dividends paid	(29.8)	(31.3)	(26.8)	(26.8)	(31.0)	Food Ingredients	13.5	23.1	21.5	20.5	21.4
Equity raised/(returned)	0	0	0	0	0	Overheads/IFRS-16 impact	(13.6)	(9.2)	(16.0)	(15.9)	(15.9)
<b>(Increase)/decrease in net debt</b>	<b>173.5</b>	<b>(9.7)</b>	<b>(0.1)</b>	<b>9.6</b>	<b>11.7</b>	<b>Underlying EBITDA</b>	<b>52.7</b>	<b>53.9</b>	<b>48.5</b>	<b>55.3</b>	<b>61.5</b>
<b>Balance Sheet (NZ\$m)</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>	<b>2023E</b>	<b>EBITDA margin (%)</b>					
Working capital	27.2	20.1	26.7	29.6	31.3	Horticulture	18.1	14.5	17.0	18.0	19.0
Fixed assets	165.7	181.3	192.3	201.4	209.6	Logistics	7.6	8.5	6.5	7.0	7.0
Intangibles	43.8	41.9	41.9	41.9	41.9	Food Ingredients	8.7	13.3	11.2	9.7	9.5
Right of use asset	78.8	77.9	75.7	73.5	71.4	<b>Total</b>	<b>10.9</b>	<b>11.5</b>	<b>10.2</b>	<b>10.5</b>	<b>11.0</b>
Other assets	62.7	87.8	85.6	87.9	89.9						
<b>Total funds employed</b>	<b>378.2</b>	<b>409.0</b>	<b>422.2</b>	<b>434.3</b>	<b>444.1</b>	<b>Apple volumes ('000 TCE)</b>					
Net debt/(cash)	(104.9)	(98.5)	(92.2)	(98.1)	(106.0)	Premium varieties	2,095	2,238	2,170	2,325	2,478
Lease liability	70.7	70.2	82.2	84.0	85.5	Traditional varieties	1,727	1,677	1,633	1,609	1,619
Other liabilities	53.4	58.9	49.6	52.4	52.4	<b>Total</b>	<b>3,822</b>	<b>3,915</b>	<b>3,803</b>	<b>3,934</b>	<b>4,097</b>
Shareholder's funds	355.0	373.8	377.9	391.3	407.5						
Minority interests	4.0	4.6	4.6	4.6	4.6						
<b>Total funding sources</b>	<b>378.2</b>	<b>409.0</b>	<b>422.2</b>	<b>434.3</b>	<b>444.1</b>						

\* Forsyth Barr target prices reflect valuation rolled forward at cost of equity less the next 12-months dividend

## FY20 result summary

SCL reported a well signalled soft FY20 result, with Underlying NPAT of NZ\$33.8m down -7% on the prior period, albeit ahead of our expectations of NZ\$30m. A softer Horticulture result was the key driver of earnings weakness, with suppressed apple prices in Asia although largely offset by significant growth in the Food Ingredients business.

SCL announced a final dividend of 9.5cps.

### Divisional breakdown

- **Horticulture (underlying EBITDA NZ\$31m, down -21% on the prior year)** – Horticulture revenue fell -7% as weak apple prices in Asian markets weighed on performance (average premium apple prices fell -7% on the prior comparable period). Price weakness was largely driven by the timing of lockdowns, resulting in high stocks of domestic fruit in China during the New Zealand selling period.
  - We view Asian market pricing weakness as mostly a one-off impact, however, recent market anecdotes suggest pricing for imported fruit remains below pre COVID-19 levels. Conversely, the European market is exhibiting a robust pricing backdrop following weak domestic crops.
  - Margin is expected to be suppressed in FY21, with less seasonal workers available due to border closures and therefore more higher cost (less productive) domestic workforce. SCL signalled a higher need to invest in further mechanisation of the picking process in order to combat recent wage inflation.
- **Food Ingredients (NZ\$23.1m, +70%)** – The result was underpinned by its Shelby pet food business, with pet food demand benefitting from a COVID-19 tailwind. Volume sold (+4%) and price achieved (+7%) were both up on the prior year, however, the significant earnings uplift came from margin expansion (FY20 EBITDA margin 13% vs FY19 of 9%).
  - Sourcing contracts are typically negotiated on a 12-month basis. We suspect meat processors will be more aggressive around pricing agreements given the well publicised strength in the pet food sector. We factor in some reversion of margin towards historical levels.
  - Top line growth in this business has been encouraging and we expect it to continue to benefit from the structural tailwind. However, management commentary suggests travel restrictions have limited new off-take agreements and possible bolt-acquisitions in the coming year.
- **Logistics (NZ\$3.4m, +4%)** – Solid result amid COVID-19 disruption, up +3% on the prior year despite a decline in volumes shipped.
  - Outlook appears more challenging given exposure to New Zealand summer fruit which has been impacted by hail events.

Figure 1. FY20 result summary (NZ\$m)

	FY19	FY20	% chg	Comments
Revenue	484.6	470.7	-2.9%	Lower Horticulture revenue (-7%) offset by Food Ingredients growth (+12%)
Horticulture	39.7	31.4	-20.9%	Soft apple prices in Asia. Average realised price for premium apples -7.3% vs. pcip
Food Ingredients	13.5	23.1	71.1%	Strong demand, sales up +12%, with material EBITDA margin expansion - FY20 13% vs. FY19 9%
Logistics	3.3	3.4	3.0%	Freight volumes down -10% vs. pcip, offset by margin expansion
Corporate	(3.8)	(4.0)	5.3%	
Underlying EBITDA	52.7	53.9	2.3%	Post-IFRS 16 Underlying EBITDA NZ\$64.2m
D&A	(10.2)	(10.9)	6.9%	
Underlying EBIT	42.5	43.0	1.2%	
Interest & tax	(6.1)	(9.2)	50.8%	Net interest revenue of NZ\$0.7m (pre-IFRS 16)
Underlying NPAT	36.4	33.8	-7.1%	
Reported NPAT	121.6	26.6	n/a	Adjustments include impairment of some orchards (NZ\$4.3m)
EPS (cps)	25.9	24.0	-7.1%	
Final DPS (cps)	9.5	9.5	n/a	Full year dividend of 19cps (flat on prior year), payout ratio 127%
<b>Balance sheet &amp; cashflow</b>				
Working capital	24.3	18.5	-23.8%	NZ\$19.5 growth capex. Orchard redevelopment and Whakatu coldstore
Net debt / (cash)	(104.9)	(98.5)	-6.1%	Material net cash balance. International bolt-on strategy slowed by COVID
Capex	15.7	24.5	56.1%	Orchard redevelopment and whakatu coldstore. FY21 capex likely to be at a maintenance level
Operating cashflow	56.1	53.2	-5.1%	

Source: SCL, Forsyth Barr analysis

## Earnings changes and investment view

We lower our FY21E NPAT forecast -13% to NZ\$29.5m, slightly below the mid-point of the guidance range (NZ\$27.5m to NZ\$33.5m). Earnings changes reflect lower Horticulture margin and a drop in Logistics contribution. We assume lower earnings contributions from all three divisions in FY21. We also lower our FY22E NPAT as we factor in a higher labour cost assumption. Earnings changes are more limited in FY22E and beyond, as higher average realised apple prices (mix driven) offset the rising cost base.


**Figure 2. Earnings changes (NZ\$m)**

	old	FY21 new	% chg	old	FY22 new	% chg	old	FY23 new	% chg
Sales	495.0	475.9	-3.9%	528.4	526.6	-0.3%	557.0	557.1	0.0%
EBITDA	64.1	59.2	-7.6%	69.7	65.8	-5.6%	75.2	72.0	-4.3%
EBITDA (pre-IFRS 16)	52.9	48.5	-8.3%	59.2	55.3	-6.6%	63.7	61.5	-3.4%
<b>NPAT</b>	33.9	29.5	-13.0%	37.2	35.0	-5.8%	40.5	39.5	-2.5%
EPS (cps)	24.1	20.9	-13.1%	26.4	24.9	-6.0%	28.8	28.0	-2.7%
DPS (cps)	21.0	19.0	-9.5%	22.0	21.0	-4.5%	23.0	22.0	-4.3%

Source: Forsyth Barr analysis

## We lower our target price -30cps to NZ\$5.00; NEUTRAL

We lower our target price 30cps (-6%) to NZ\$5.00, reflecting a lower margin backdrop for Horticulture and changes to our cost of capital assumptions. Our WACC estimate has increased from 6.5% to 6.9% following changes to our risk free rate (from 1.3% to 2.3%) and market risk premium (from 6.0% to 5.5%), consistent with our strategy report, *Still a One Way Bet? – Updated WACC Assumptions*, published 12 February 2021.

**Figure 3. Price performance**


Source: Forsyth Barr analysis

**Figure 4. Substantial shareholders**

Shareholder	Latest Holding
China Resources	15.4%
Harbour Asset Management & Jarden Securities Limited	10.0%
Salt Funds Management	5.0%


Source: NZX, Forsyth Barr analysis, NOTE: based on SPH notices only

**Figure 5. International valuation comparisons**


Company	Code	Price	Mkt Cap (m)	PE 2021E	PE 2022E	EV/EBITDA 2021E	EV/EBITDA 2022E	EV/EBIT 2021E	EV/EBIT 2022E	Cash Yld 2022E
(metrics re-weighted to reflect SCL's balance date - December)										
Scales	SCL NZ	NZ\$4.60	NZ\$648	22.0x	18.5x	9.3x	8.3x	13.3x	11.5x	4.6%
DELEGAT GROUP *	DGL NZ	NZ\$15.00	NZ\$1,517	21.0x	19.3x	13.8x	12.9x	15.8x	14.7x	1.3%
COMVITA *	CVT NZ	NZ\$3.20	NZ\$224	18.9x	15.1x	10.8x	9.7x	18.7x	15.4x	1.7%
FONTERRA *	FSF NZ	NZ\$5.03	NZ\$8,115	16.6x	15.0x	8.7x	8.4x	15.0x	14.3x	3.3%
SANFORD *	SAN NZ	NZ\$4.45	NZ\$416	14.1x	9.1x	7.8x	6.0x	12.4x	8.7x	5.2%
NEW ZEALAND KING SALMON *	NZK NZ	NZ\$1.47	NZ\$204	31.3x	12.8x	10.4x	6.8x	19.7x	9.8x	3.4%
Compco Average:				20.4x	14.3x	10.3x	8.7x	16.3x	12.6x	3.0%
SCL Relative:				8%	30%	-10%	-4%	-19%	-9%	52%

EV = Current Market Cap + Actual Net Debt

Source: \*Forsyth Barr analysis, Bloomberg Consensus, Compco metrics re-weighted to reflect headline (SCL) companies fiscal year end

**Figure 6. Consensus EPS momentum (NZ\$)**


Source: Forsyth Barr analysis

**Figure 7. One year forward PE (x)**


Source: Forsyth Barr analysis

**Analyst certification:** The research analyst(s) primarily responsible for the preparation and content of this publication ("**Analysts**") are named on the first page of this publication. Each such Analyst certifies (other than in relation to content or views expressly attributed to another analyst) that (i) the views expressed in this publication accurately reflect their personal views about each issuer and financial product referenced and were prepared in an independent manner, including with respect to Forsyth Barr Limited and its related companies; and (ii) no part of the Analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that Analyst in this report.

**Analyst holdings:** The following Analyst(s) have a threshold interest in the financial products referred to in this publication: N/A. For these purposes, a threshold interest is defined as being a holder of more than \$50,000 in value or 1% of the financial products on issue, whichever is the lesser.

**Ratings distributions:** As at 26 Feb 2021, Forsyth Barr's research ratings were distributed as follows:

<b>OUTPERFORM</b>	<b>NEUTRAL</b>	<b>UNDERPERFORM</b>
<b>42.3%</b>	<b>38.5%</b>	<b>19.2%</b>

Forsyth Barr's research ratings are OUTPERFORM, NEUTRAL, and UNDERPERFORM. The ratings are relative to our other equity security recommendations across our New Zealand market coverage and are based on risk-adjusted Estimated Total Returns for the securities in question. Risk-adjusted Estimated Total Returns are calculated from our assessment of the risk profile, expected dividends and target price for the relevant security.

**Disclosure:** Forsyth Barr Limited and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) investment banking or other services to, the issuer of those financial products (and may receive fees for so acting). Forsyth Barr is not a registered bank within the meaning of the Reserve Bank of New Zealand Act 1989. Forsyth Barr may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. Forsyth Barr confirms no inducement has been accepted from the issuer(s) that are the subject of this publication, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the issuer(s) being researched.

**Investment banking engagements:** Other than confidential engagements, Forsyth Barr has not within the past 12 months been engaged to provide investment banking services to the issuer that is the subject of this publication. For information about whether Forsyth Barr has within the past 12 months been engaged to provide investment banking services to any other issuer referred to in this publication, please refer to the most recent research report for that issuer's financial products.

**Not personalised financial advice:** The recommendations and opinions in this publication do not take into account your personal financial situation or investment goals. The financial products referred to in this publication may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Adviser. The value of financial products may go up and down and investors may not get back the full (or any) amount invested. Past performance is not necessarily indicative of future performance. Disclosure statements for Forsyth Barr Investment Advisers are available on request and free of charge.

**Disclaimer:** This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. Forsyth Barr does not make any representation or warranty (express or implied) that the information in this publication is accurate or complete, and, to the maximum extent permitted by law, excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice to you. Any analyses or valuations will typically be based on numerous assumptions; different assumptions may yield materially different results. Nothing in this publication should be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from doing so, or to engage in any other transaction. This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction.

**Terms of use:** Copyright Forsyth Barr Limited. You may not redistribute, copy, revise, amend, create a derivative work from, extract data from, or otherwise commercially exploit this publication in any way. By accessing this publication via an electronic platform, you agree that the platform provider may provide Forsyth Barr with information on your readership of the publications available through that platform.